Core Viewpoint - The control change of Asia-Pacific Pharmaceutical (002370.SZ) has been revealed, with the controlling shareholder planning to transfer 1.09 billion shares at a price of 8.26 CNY per share, totaling 900 million CNY, marking a significant shift in ownership to Xinghao Holdings and its actual controller, Qiu Zhongxun [2][3]. Group 1: Share Transfer Details - The share transfer price of 8.26 CNY per share represents a premium of 45.68% over the closing price of 5.67 CNY per share on September 26, prior to the agreement signing [3]. - The original shareholders, including Fubon Group and Han Gui Investment, will exit with nearly double their investment, achieving an approximate 80% return on their investment [6][7]. - Fubon Group and its associates acquired shares through various methods, including judicial auctions and market purchases, with an average acquisition cost estimated at 4.6 CNY per share [6][4]. Group 2: Financial Position and Future Plans - As of mid-2025, Asia-Pacific Pharmaceutical has 625 million CNY in cash and a low debt ratio of 9.14%, indicating a strong financial position [8]. - The share transfer agreement includes performance and asset quality commitments, with a target revenue of at least 360 million CNY for 2025 and a net profit loss not exceeding 70 million CNY [10]. - The company plans to transition from traditional chemical generics to innovative drug development, with a focus on potential new drug projects that have already shown preliminary research results [18][19].

Core Viewpoint - The controlling shareholder of Asia-Pacific Pharmaceutical will change from Fubon Group to Xinghao Holdings, with the stock resuming trading on October 14, 2025 [2][5]. Shareholder Change - Fubon Group and Hangu Investment plan to transfer 14.62% of shares, totaling 108.9 million shares, at a price of 8.26 CNY per share, amounting to 900 million CNY [4]. - After the transfer, the controlling shareholder will be Xinghao Holdings, and the actual controllers will change to Qiu Zhongxun [4]. Corporate Restructuring - Asia-Pacific Pharmaceutical's board approved the dissolution of its wholly-owned subsidiary, Wuhan Guanggu Asia-Pacific Pharmaceutical, to optimize organizational structure and improve operational efficiency [5]. - The subsidiary will no longer be included in the consolidated financial statements after the dissolution [5]. Fundraising and Investment - The company announced a targeted fundraising plan to issue up to 137 million shares at a price of 5.11 CNY per share, raising a total of up to 700 million CNY [7]. - The funds will be used for new drug research and development projects, including oncolytic virus drug platforms and long-acting formulations [7][8]. - The issuance will not change the company's control but may dilute net asset returns and earnings per share in the short term [7]. Strategic Direction - The company aims to transition from traditional chemical generics to improved new drugs and innovative drug research, enhancing its risk resistance and expanding its product portfolio [8].

Core Viewpoint - The controlling shareholder of Asia-Pacific Pharmaceutical will change from Fubon Group to Xinghao Holdings, with the stock resuming trading on October 14, 2025 [1][3]. Shareholder Control Change - Fubon Group and Hangu Investment plan to transfer 14.62% of the company's shares, totaling 108.9 million shares, at a price of 8.26 CNY per share, amounting to a total of 900 million CNY [2]. - Following the transfer, the controlling shareholder will shift to Xinghao Holdings, and the actual controller will change to Qiu Zhongxun [2]. Stock Resumption and Subsidiary Deregistration - Asia-Pacific Pharmaceutical's stock will resume trading on October 14, 2025 [3]. - The company has approved the deregistration of its wholly-owned subsidiary, Wuhan Optics Valley Asia-Pacific Pharmaceutical Co., Ltd., which will no longer be included in the consolidated financial statements after deregistration [3]. Fundraising and Investment Plans - The company plans to issue up to 137 million shares at a price of 5.11 CNY per share, raising a total of no more than 700 million CNY for new drug research and development projects [4]. - The fundraising will focus on developing oncolytic virus drug platforms, long-acting formulations, and compound formulations, among others [4]. - The issuance will not change the company's control but will increase total share capital and net assets, potentially diluting net asset returns and earnings per share in the short term [4]. Strategic Transition - Through the implementation of the fundraising projects, the company aims to transition from a focus on traditional chemical generics to improved new drugs and first-class innovative drug research and development [5]. - This strategic shift is intended to enhance the company's operational resilience and advance promising new drug projects into critical clinical stages, thereby broadening its product portfolio [5].